1:00 PM ET | 12:00 PM CT | 11:00 AM MT | 10:00 AM PT
With Tahseen Mozaffar, MD, chair of neurology at the University of California Irvine. Learn about clinical trials, the scientific process by which researchers determine whether a new therapy is safe, works biologically as expected, and, most importantly, can improve outcomes for patients. In addition, trial sponsors need to navigate a complex web of regulatory rules set by the FDA in the U.S. (and European Medicines Agency, or EMA, in Europe). There’s a lot to unpack here, especially when it comes to a complex condition like FSH muscular dystrophy. We will discuss the real-life, ongoing ReDUX4 trial, the first trial of a DUX4-reducing therapeutic, which is expected to announce results by the end of June 2021. This webinar will help you understand the trial results, whether positive or negative, and what they mean.
Please register by clicking on the button to get your personalized link to attend the webinar.